A notable advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This updated offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and provides https://victorpxxp965800.wikijm.com/2243693/revolutionary_approach_tirzepatide_45mg_for_blood_sugar_management